Volastra Therapeutics

📍 New York, United States🗓 Founded 2019👥 45 employees💰 Last funded Jun 2024
Biotechnology🌐 volastratx.com
Website LinkedIn
Volastra Therapeutics is a New York-based drug discovery and therapeutics company pioneering novel approaches to treating cancer by exploiting chromosomal instability (CIN), cancer’s most targetable vulnerability. Founded by Lewis Cantley, Ph.D., Olivier Elemento, Ph.D., and Samuel Bakhoum, M.D., Ph.D., Volastra is advancing a novel synthetic lethal and immune activating pipeline. Leading its portfolio, Volastra has two KIF18A inhibitors in Phase 1 clinical trials for cancers with high levels of chromosomal instability.
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2019
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Volastra Therapeutics?
Volastra Therapeutics has 1 investors on record on gritt.io, 1 mid-stage.
When did Volastra Therapeutics last raise funding?
The most recent investment in Volastra Therapeutics recorded on gritt.io was in June 2024.
When was Volastra Therapeutics founded?
Volastra Therapeutics was founded in 2019.
What industry is Volastra Therapeutics in?
Volastra Therapeutics operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Volastra Therapeutics based?
Volastra Therapeutics is headquartered in New York, United States.